Par Pharmaceutical Begins Shipment of Ofloxacin Tablets for Bacterial Infections
September 3, 2003
SPRING VALLEY, N.Y. -- Pharmaceutical Resources, Inc. announced today that its principal subsidiary, Par Pharmaceutical, has received FDA approval for its ANDA for ofloxacin tablets in 200 mg, 300 mg and 400 mg strengths. Shipment of the 400 mg strength with branded sales of approximately $15 million will begin immediately. It is anticipated the remaining two strengths will ship sometime during the next quarter.
Ofloxacin is the generic version of Ortho-McNeil's Floxin, which is indicated for the treatment of adults with mild to moderate bacterial infections. The Floxin brand has annual sales of approximately $30 million.
Pharmaceutical Resources, Inc., a holding company, develops, manufactures, and distributes generic pharmaceuticals through its wholly owned subsidiary, Par Pharmaceutical.
